Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Call Options Transaction History
Atlas Venture Life Science Advisors, LLC
- $443 Million
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
220Shares Held
130MCall Options Held
36.5KPut Options Held
138K-
Vanguard Group Inc Valley Forge, PA9.76MShares$182 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$181 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$176 Million0.05% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$138 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$102 Million14.09% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $967M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...